PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
23243450-3	2012	ICB synergistically decreased the formation of bone resorption pits, the number of multinucleated osteoclasts, and the activity of tartrate-resistant acid phosphatase (TRAP) and showed antagonistic or additive effects on cathepsin K activity in the coculture system of osteoblasts and bone marrow cells in the presence of 1, 25-dihydroxyvitamin D(3) and dexamethasone.	indole-2-carboxylic acid	0-3	cathepsin K	Rattus norvegicus	221-232
22462704-2	2012	The authors report a case of vasculopathy after ICB injection for a recurrent cystic CRP.	indole-2-carboxylic acid	48-51	C-reactive protein	Homo sapiens	85-88
23243450-5	2012	In addition, ICB synergistically improved the ratio of protein expression of osteoprotegerin (OPG) and RANKL in osteoblasts and interfered with the mitogen-activated protein kinases (MAPKs) pathway in osteoclast.	indole-2-carboxylic acid	13-16	TNF receptor superfamily member 11B	Rattus norvegicus	77-92
23243450-5	2012	In addition, ICB synergistically improved the ratio of protein expression of osteoprotegerin (OPG) and RANKL in osteoblasts and interfered with the mitogen-activated protein kinases (MAPKs) pathway in osteoclast.	indole-2-carboxylic acid	13-16	TNF receptor superfamily member 11B	Rattus norvegicus	94-97
23243450-5	2012	In addition, ICB synergistically improved the ratio of protein expression of osteoprotegerin (OPG) and RANKL in osteoblasts and interfered with the mitogen-activated protein kinases (MAPKs) pathway in osteoclast.	indole-2-carboxylic acid	13-16	TNF superfamily member 11	Rattus norvegicus	103-108
20570996-8	2010	The expressions of the mRNA of interleukin (IL)-1alpha, IL-6, tumor necrosis factor (TNF)-alpha, and granulocyte macrophage-colony stimulating factor (GM-CSF) in the ICB of the two groups of mice were compared.	indole-2-carboxylic acid	166-169	interleukin 1 alpha	Mus musculus	31-54
21351868-11	2011	Aqueous and ICB bromfenac levels exceeded its IC(50) for COX-2 at peak and trough, but not for COX-1 at trough aqueous levels and peak and trough ICB levels.	indole-2-carboxylic acid	12-15	cytochrome c oxidase subunit II	Oryctolagus cuniculus	57-62
21692033-11	2011	CD163+ cells in the parenchyma (activated microglia/macrophages) increased significantly within 24 hours after trauma and ischemia and within 1-7 days following ICB or hypoxia.	indole-2-carboxylic acid	161-164	CD163 molecule	Homo sapiens	0-5
20570996-8	2010	The expressions of the mRNA of interleukin (IL)-1alpha, IL-6, tumor necrosis factor (TNF)-alpha, and granulocyte macrophage-colony stimulating factor (GM-CSF) in the ICB of the two groups of mice were compared.	indole-2-carboxylic acid	166-169	interleukin 6	Mus musculus	56-60
20570996-8	2010	The expressions of the mRNA of interleukin (IL)-1alpha, IL-6, tumor necrosis factor (TNF)-alpha, and granulocyte macrophage-colony stimulating factor (GM-CSF) in the ICB of the two groups of mice were compared.	indole-2-carboxylic acid	166-169	tumor necrosis factor	Mus musculus	62-95
20570996-8	2010	The expressions of the mRNA of interleukin (IL)-1alpha, IL-6, tumor necrosis factor (TNF)-alpha, and granulocyte macrophage-colony stimulating factor (GM-CSF) in the ICB of the two groups of mice were compared.	indole-2-carboxylic acid	166-169	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	101-149
20570996-8	2010	The expressions of the mRNA of interleukin (IL)-1alpha, IL-6, tumor necrosis factor (TNF)-alpha, and granulocyte macrophage-colony stimulating factor (GM-CSF) in the ICB of the two groups of mice were compared.	indole-2-carboxylic acid	166-169	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	151-157
20035322-6	2010	The results showed that ICB, which mainly blocks large-diameter myelinated muscle afferents, was associated with an increase in PPT and PTRP (all P < 0.001) at MTrP regions but not at non-MTrP regions.	indole-2-carboxylic acid	24-27	lysosomal protein transmembrane 4 alpha	Homo sapiens	163-167
20035322-6	2010	The results showed that ICB, which mainly blocks large-diameter myelinated muscle afferents, was associated with an increase in PPT and PTRP (all P < 0.001) at MTrP regions but not at non-MTrP regions.	indole-2-carboxylic acid	24-27	lysosomal protein transmembrane 4 alpha	Homo sapiens	191-195
15979396-1	2006	Ternary complexes of Co(II), Ni(II) and Cu(II) with indole-2-carboxylic acid (A) and 4-substituted hydrazinethiocarbamide (L) [4-phenylhydrazinethiocarbamide (L1), 4-benzylhydrazinethiocarbamide (L2) and 4-(2-propenyl)hydrazinethiocarbamide (L3)] were prepared.	indole-2-carboxylic acid	52-76	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	21-27
16934231-4	2006	Nicotine (0.625, 1.25, 2.5, 5 ng; ICB) markedly attenuated Delta(9)-THC ataxia dose dependently, which was abolished by ICB hexamethonium (5 microg), thus suggesting that the attenuation by nicotine occurred via the nicotinic acetylcholine receptor (nAChR).	indole-2-carboxylic acid	34-37	cholinergic receptor, nicotinic, alpha polypeptide 7	Mus musculus	250-255
16876468-1	2006	Ternary complexes of Co(II), Ni(II) and Cu(II) with indole-2-carboxylic acid (A) and 4-substituted hydrazinethiocarbamide (L) [4-phenylhydrazinethiocarbamide (L(1)), 4-benzylhydrazinethiocarbamide (L(2)) and 4-(2-propenyl)hydrazinethiocarb-amide (L(3)) were prepared.	indole-2-carboxylic acid	52-76	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	21-27
18757518-10	2008	RESULTS: IL-10 gene expression in ICB was significantly upregulated for at least 1 month.	indole-2-carboxylic acid	34-37	interleukin 10	Rattus norvegicus	9-14
18757518-11	2008	Immunohistochemical examination indicated that dendritic cells in the ICB produced IL-10.	indole-2-carboxylic acid	70-73	interleukin 10	Rattus norvegicus	83-88
18321717-2	2008	In continuation of our attempts to develop novel cPLA(2)alpha inhibitors, a series of structurally related indole-2-carboxylic acids containing 3-aryloxy-2-oxopropoxy residues in position 5 were synthesized and tested for their cPLA(2)alpha-inhibitory potency.	indole-2-carboxylic acid	107-132	phospholipase A2 group IVA	Homo sapiens	49-61
15999990-0	2005	Probing the subpockets of factor Xa reveals two binding modes for inhibitors based on a 2-carboxyindole scaffold: a study combining structure-activity relationship and X-ray crystallography.	indole-2-carboxylic acid	88-103	coagulation factor X	Homo sapiens	26-35
16254941-2	2005	Binding of nuclear factor-Y (NF-Y) to the ICB site upregulates MDR1 gene expression and is, therefore, a good target for anticancer therapeutic agents.	indole-2-carboxylic acid	42-45	ATP binding cassette subfamily B member 1	Homo sapiens	63-67
16254941-7	2005	DNase I-footprinting assays were carried out with the topoisomerase IIalpha-promoter sequence, which contains five ICB sites; of these, ICB1 and ICB5 are similar to the ICB site of MDR1.	indole-2-carboxylic acid	115-118	thymocyte selection associated family member 2	Homo sapiens	136-140
15999990-1	2005	Structure-activity relationships within a series of highly potent 2-carboxyindole-based factor Xa inhibitors incorporating a neutral P1 ligand are described with particular emphasis on the structural requirements for addressing subpockets of the factor Xa enzyme.	indole-2-carboxylic acid	66-81	coagulation factor X	Homo sapiens	88-97
15999990-1	2005	Structure-activity relationships within a series of highly potent 2-carboxyindole-based factor Xa inhibitors incorporating a neutral P1 ligand are described with particular emphasis on the structural requirements for addressing subpockets of the factor Xa enzyme.	indole-2-carboxylic acid	66-81	coagulation factor X	Homo sapiens	246-255
11039188-0	2000	Comparison of the inhibition of the cytosolic phospholipase A2-mediated arachidonic acid release by several indole-2-carboxylic acids and 3-(pyrrol-2-yl)propionic acids in bovine and in human platelets.	indole-2-carboxylic acid	108-133	phospholipase A2 group IVA	Bos taurus	36-62
11423093-2	2001	We have demonstrated an accentuation of cannabinoid (CP55,940)-induced motor incoordination in mice by the adenosine A(1) receptor-selective agonist N(6)-cyclohexyladenosine (CHA) (4 ng) using an intracerebellar (ICB) microinjection method.	indole-2-carboxylic acid	213-216	adenosine A1 receptor	Mus musculus	107-130
15333039-6	2004	RESULTS: In controls given solvent at 4 h, ICB was on average 8.8 micro L, which was significantly increased with 10 mg kg(-1) microPli and with 4 and 8 mg kg(-1) tPA to 12-13 micro L (P < 0.05 each vs. controls, n = 7-9), whereas 5 mg kg(-1) microPli did not affect bleeding (8.5 micro L P = NS vs. controls, n = 7).	indole-2-carboxylic acid	43-46	plasminogen activator, tissue	Mus musculus	163-166
15261268-0	2004	Factor Xa inhibitors based on a 2-carboxyindole scaffold: SAR of neutral P1 substituents.	indole-2-carboxylic acid	32-47	coagulation factor X	Homo sapiens	0-9
15261268-1	2004	A series of novel, highly potent 2-carboxyindole-based factor Xa inhibitors is described.	indole-2-carboxylic acid	33-48	coagulation factor X	Homo sapiens	55-64
15261268-2	2004	Structural requirements for neutral ligands, which bind in the S1 pocket of factor Xa were investigated with the 2-carboxyindole scaffold.	indole-2-carboxylic acid	113-128	coagulation factor X	Homo sapiens	76-85
11039188-1	2000	The inhibition of the cytosolic phospholipase A2 (cPLA2)-mediated arachidonic acid release by several indole-2-carboxylic acids and 3-(pyrrol-2-yl)propionic acids was measured in intact human platelets using calcium ionophore A23187 as stimulant.	indole-2-carboxylic acid	102-127	phospholipase A2 group IVA	Homo sapiens	22-48
11039188-1	2000	The inhibition of the cytosolic phospholipase A2 (cPLA2)-mediated arachidonic acid release by several indole-2-carboxylic acids and 3-(pyrrol-2-yl)propionic acids was measured in intact human platelets using calcium ionophore A23187 as stimulant.	indole-2-carboxylic acid	102-127	phospholipase A2 group IVA	Homo sapiens	50-55
34160685-8	2022	ICB therapy of anti-PD-1/anti-CTLA-4 antibodies promoted T-cell infiltration into tumor tissues, whereas no definite antitumor effect was observed.	indole-2-carboxylic acid	0-3	programmed cell death 1	Mus musculus	20-24
7958722-11	1994	The infusion of hemicholinium (4 microM) for 30 min together with CDP-choline completely prevented the potentiation of exogenous ACh-induced relaxation in the ICB.	indole-2-carboxylic acid	159-162	cut-like homeobox 1	Rattus norvegicus	66-69
7958722-13	1994	The results of the present work suggest that CDP-choline is acting by increasing choline levels in the cholinergic nerve terminals of the ICB, increasing the synthesis and/or release of ACh.	indole-2-carboxylic acid	138-141	cut-like homeobox 1	Rattus norvegicus	45-48
1336536-10	1992	RAPA (10mg/kg) inhibited the AH leukocytes and protein content and MPO activity in the ICB.	indole-2-carboxylic acid	87-90	myeloperoxidase	Oryctolagus cuniculus	67-70
34160685-8	2022	ICB therapy of anti-PD-1/anti-CTLA-4 antibodies promoted T-cell infiltration into tumor tissues, whereas no definite antitumor effect was observed.	indole-2-carboxylic acid	0-3	cytotoxic T-lymphocyte-associated protein 4	Mus musculus	30-36
34925348-17	2021	Finally translocation-related sarcomas are heterogeneous, and although synovial sarcomas a poorly infiltrated and have a poor response rate to ICI, ASPS largely benefit from ICB monotherapy or its association with antiangiogenics agents.	indole-2-carboxylic acid	174-177	ASPSCR1 tether for SLC2A4, UBX domain containing	Homo sapiens	148-152
34873175-4	2021	In mouse models of PDAC, either tumor cell-specific depletion or pharmacologic inhibition of GR leads to PD-L1 downregulation and MHC-I upregulation in tumor cells, which in turn promotes the infiltration and activity of cytotoxic T cells, enhances anti-tumor immunity, and overcomes resistance to ICB therapy.	indole-2-carboxylic acid	298-301	nuclear receptor subfamily 3, group C, member 1	Mus musculus	93-95
34733790-11	2021	Hence, PLA2G2D could be a novel potential biomarker for immune cell infiltration, patient survival, and the response to ICB therapy in CSCC and may represent a promising target for the treatment of CSCC patients.	indole-2-carboxylic acid	120-123	phospholipase A2 group IID	Homo sapiens	7-14
34622157-6	2021	Furthermore, the mutual interactions between epithelial-to-mesenchymal-transition, m6A-RNA-methylation, and MTDH may illustrate the potential mechanisms of MTDH resistant to ICB treatment.	indole-2-carboxylic acid	174-177	metadherin	Homo sapiens	108-112
34622157-6	2021	Furthermore, the mutual interactions between epithelial-to-mesenchymal-transition, m6A-RNA-methylation, and MTDH may illustrate the potential mechanisms of MTDH resistant to ICB treatment.	indole-2-carboxylic acid	174-177	metadherin	Homo sapiens	156-160
35024441-8	2022	In addition, the NPs increased DAC stability and improved IFN-gamma secretion and the anti-tumor effect of ICB in vitro.	indole-2-carboxylic acid	107-110	interferon gamma	Sus scrofa	58-67
35314795-7	2022	In the ICB-resistant mouse model, the chemokine was sufficient to enable a successful anti-PD-L1 therapy.	indole-2-carboxylic acid	7-10	CD274 antigen	Mus musculus	91-96
35621713-9	2022	Whereas parental MOC2 tumors were resistant to ICB treatment, K17KO MOC2 tumors that did not spontaneously regress were eliminated upon ICB treatment.	indole-2-carboxylic acid	136-139	keratin 17	Homo sapiens	62-72
35621713-12	2022	CONCLUSIONS: We demonstrate that K17 expression in HNSCC contributes to immune evasion and resistance to ICB treatment by broadly altering immune landscapes of tumors.	indole-2-carboxylic acid	105-108	keratin 17	Homo sapiens	33-36
35366569-10	2022	Thus, early on-treatment CRP kinetics is a promising low-cost and easy-to-implement biomarker to optimise therapy monitoring in patients with mUC treated with ICB.	indole-2-carboxylic acid	159-162	C-reactive protein	Homo sapiens	25-28
35558087-10	2022	SPP1 expression was dramatically upregulated, and SPP1+ TAM gene signatures were enriched in TAMs receiving ICB therapy.	indole-2-carboxylic acid	108-111	secreted phosphoprotein 1	Homo sapiens	0-4
35558087-10	2022	SPP1 expression was dramatically upregulated, and SPP1+ TAM gene signatures were enriched in TAMs receiving ICB therapy.	indole-2-carboxylic acid	108-111	secreted phosphoprotein 1	Homo sapiens	50-54
35558087-10	2022	SPP1 expression was dramatically upregulated, and SPP1+ TAM gene signatures were enriched in TAMs receiving ICB therapy.	indole-2-carboxylic acid	108-111	Myeloproliferative syndrome, transient (transient abnormal myelopoiesis)	Homo sapiens	56-59
35236758-4	2022	Here, we show that a recently defined CAF subset characterized by the expression of Meflin, a glycosylphosphatidylinositol-anchored protein marker of mesenchymal stromal/stem cells, is associated with survival and favorable therapeutic response to ICB monotherapy in patients with non-small cell lung cancer (NSCLC).	indole-2-carboxylic acid	248-251	immunoglobulin superfamily containing leucine rich repeat	Homo sapiens	84-90
35241815-2	2022	Here we report the design and performance of systemically administered protease activity sensors conjugated to anti-programmed cell death protein 1 (alphaPD1) antibodies for the monitoring of antitumour responses to ICB therapy.	indole-2-carboxylic acid	216-219	programmed cell death 1	Homo sapiens	116-147
35241815-4	2022	By using syngeneic mouse models of colorectal cancer, we show that random forest classifiers trained on mass spectrometry signatures from a library of alphaPD1-conjugated mass-barcoded activity sensors for differentially expressed tumour proteases and immune proteases can be used to detect early antitumour responses and discriminate resistance to ICB therapy driven by loss-of-function mutations in either the B2m or Jak1 genes.	indole-2-carboxylic acid	349-352	beta-2 microglobulin	Mus musculus	412-415
35241815-4	2022	By using syngeneic mouse models of colorectal cancer, we show that random forest classifiers trained on mass spectrometry signatures from a library of alphaPD1-conjugated mass-barcoded activity sensors for differentially expressed tumour proteases and immune proteases can be used to detect early antitumour responses and discriminate resistance to ICB therapy driven by loss-of-function mutations in either the B2m or Jak1 genes.	indole-2-carboxylic acid	349-352	Janus kinase 1	Mus musculus	419-423
34092233-2	2021	The objective here was to identify the feasibility and mechanism of RAS/RAF/PI3K pathway inhibition in melanoma to sensitize tumors to ICB therapy.	indole-2-carboxylic acid	135-138	zinc fingers and homeoboxes 2	Homo sapiens	72-75
35525080-0	2022	Design, synthesis and antitumor evaluation of novel 1H-indole-2-carboxylic acid derivatives targeting 14-3-3eta protein.	indole-2-carboxylic acid	52-79	tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein eta	Homo sapiens	102-111
35525080-1	2022	In this work, a series of novel 1H-indole-2-carboxylic acid derivatives targeting 14-3-3eta protein were designed and synthesized for treatment of liver cancer.	indole-2-carboxylic acid	32-59	tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein eta	Homo sapiens	82-91
35393553-2	2022	By examining 1714 patients across 16 cancer types, we found that high pretreatment serum albumin level predicts favorable tumor radiographic response following ICB treatment in a dose-dependent fashion.	indole-2-carboxylic acid	160-163	albumin	Homo sapiens	83-96
33889507-10	2021	Conclusions: The presence of mutated TTN in pre-treatment peripheral blood was associated with favorable objective response and survival with ICB administration.	indole-2-carboxylic acid	142-145	titin	Homo sapiens	37-40
2995422-4	1985	Whereas free labeled Cbl was still present at 72 hours after entry, the cells also bound Cbl to an intracellular binder (ICB) presumed to represent the holo enzymes dependent on Cbl.	indole-2-carboxylic acid	121-124	Cbl proto-oncogene	Homo sapiens	89-92
2995422-4	1985	Whereas free labeled Cbl was still present at 72 hours after entry, the cells also bound Cbl to an intracellular binder (ICB) presumed to represent the holo enzymes dependent on Cbl.	indole-2-carboxylic acid	121-124	Cbl proto-oncogene	Homo sapiens	89-92
15259-6	1977	Gradient elution from DEAE-Sephadex reveals that 90--95% of the ICB--Cbl elutes with methylmalonyl-CoA mutase and 5--10% elutes with methionine synthetase.	indole-2-carboxylic acid	64-67	methylmalonyl-CoA mutase	Homo sapiens	85-109
33572793-4	2021	The significance of TCF1 in the sustenance of CTL-mediated immunity against pathogens and tumors, as well as its recently observed necessity for an effective anti-tumor immune response in ICB therapy, presents TCF1 as a potentially significant biomarker and/or therapeutic target for overcoming CD8+ T cell exhaustion and resistance to ICB therapy.	indole-2-carboxylic acid	188-191	transcription factor 7	Homo sapiens	210-214
33572793-4	2021	The significance of TCF1 in the sustenance of CTL-mediated immunity against pathogens and tumors, as well as its recently observed necessity for an effective anti-tumor immune response in ICB therapy, presents TCF1 as a potentially significant biomarker and/or therapeutic target for overcoming CD8+ T cell exhaustion and resistance to ICB therapy.	indole-2-carboxylic acid	188-191	CD8a molecule	Homo sapiens	295-298
33572793-4	2021	The significance of TCF1 in the sustenance of CTL-mediated immunity against pathogens and tumors, as well as its recently observed necessity for an effective anti-tumor immune response in ICB therapy, presents TCF1 as a potentially significant biomarker and/or therapeutic target for overcoming CD8+ T cell exhaustion and resistance to ICB therapy.	indole-2-carboxylic acid	336-339	transcription factor 7	Homo sapiens	210-214
32917659-5	2020	ST2 signaling in non-tumor cells, particularly CD8+ T cells, was critical for the antitumor efficacy of ICB immunotherapy.	indole-2-carboxylic acid	104-107	ST2	Homo sapiens	0-3
33168307-0	2021	Manipulating the Wnt/beta-catenin signaling pathway to promote anti-tumor immune infiltration into the TME to sensitize ovarian cancer to ICB therapy.	indole-2-carboxylic acid	138-141	catenin (cadherin associated protein), beta 1	Mus musculus	21-33
33462142-14	2021	Our findings support the development of ERbeta agonists including S-equol in combination with ICB immunotherapy for cancer treatment.	indole-2-carboxylic acid	94-97	estrogen receptor 1 (alpha)	Mus musculus	40-46
32917659-5	2020	ST2 signaling in non-tumor cells, particularly CD8+ T cells, was critical for the antitumor efficacy of ICB immunotherapy.	indole-2-carboxylic acid	104-107	CD8a molecule	Homo sapiens	47-50
32165639-4	2020	Here we report in two different cancers sensitive to T cell-mediated rejection, that deletion of the senescence-inducing cell cycle regulators p16Ink4a/p19Arf (Cdkn2a) or p21Cip1 (Cdkn1a) in the tumour cells abrogates both the natural and the ICB-induced cancer immune control.	indole-2-carboxylic acid	243-246	cyclin dependent kinase inhibitor 2A	Homo sapiens	143-151
32861994-6	2020	Collectively, our study proved combined treatment of ERbeta agonist and PD-1 antibody reduced MDSC infiltration in the tumor and enhanced tumor response to ICB therapy.	indole-2-carboxylic acid	156-159	estrogen receptor 1 (alpha)	Mus musculus	53-59
32847986-11	2020	CD38hi macrophages produce more interferon gamma (IFN-gamma) and related cytokines, which may explain its predictive value when treated with ICB.	indole-2-carboxylic acid	141-144	CD38 molecule	Homo sapiens	0-4
32847986-11	2020	CD38hi macrophages produce more interferon gamma (IFN-gamma) and related cytokines, which may explain its predictive value when treated with ICB.	indole-2-carboxylic acid	141-144	interferon gamma	Homo sapiens	32-59
32331230-10	2020	In addition, tumor-infiltrating T cells were re-activated and secreted more IFN-gamma towards ex vivo stimulation, suggesting that other factors, including soluble mediators and metabolic milieu in tumor microenvironment may counteract the effect of ICB treatment and contribute to the tumor progression in the mice.	indole-2-carboxylic acid	250-253	interferon gamma	Mus musculus	76-85
32165639-4	2020	Here we report in two different cancers sensitive to T cell-mediated rejection, that deletion of the senescence-inducing cell cycle regulators p16Ink4a/p19Arf (Cdkn2a) or p21Cip1 (Cdkn1a) in the tumour cells abrogates both the natural and the ICB-induced cancer immune control.	indole-2-carboxylic acid	243-246	cyclin dependent kinase inhibitor 1A	Homo sapiens	180-186
31101760-10	2019	Taken together, these results demonstrate that the efficacy of ICB in pancreatic cancer is enhanced by ATM inhibition and further potentiated by radiation as a function of increased tumoral immunogenicity, underscoring the potential of ATM inhibition in combination with ICB and radiation as an efficacious treatment strategy for pancreatic cancer.	indole-2-carboxylic acid	63-66	ATM serine/threonine kinase	Homo sapiens	103-106
32158626-6	2020	Two classification groups (C1 and C2) in the training and two validation sets were identified for the efficacy of ICB via the DNN algorithm.	indole-2-carboxylic acid	114-117	T cell receptor gamma constant 1	Homo sapiens	27-36
32110280-4	2020	ICB therapy was defined as treatment with any CTLA-4, PD-1, and/or PD-L1 monoclonal antibody.	indole-2-carboxylic acid	0-3	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	46-52
32110280-4	2020	ICB therapy was defined as treatment with any CTLA-4, PD-1, and/or PD-L1 monoclonal antibody.	indole-2-carboxylic acid	0-3	programmed cell death 1	Homo sapiens	54-58
32110280-4	2020	ICB therapy was defined as treatment with any CTLA-4, PD-1, and/or PD-L1 monoclonal antibody.	indole-2-carboxylic acid	0-3	CD274 molecule	Homo sapiens	67-72
31881488-0	2020	Design, synthesis and biological evaluation of indole-2-carboxylic acid derivatives as IDO1/TDO dual inhibitors.	indole-2-carboxylic acid	47-71	indoleamine 2,3-dioxygenase 1	Homo sapiens	87-91
31881488-0	2020	Design, synthesis and biological evaluation of indole-2-carboxylic acid derivatives as IDO1/TDO dual inhibitors.	indole-2-carboxylic acid	47-71	tryptophan 2,3-dioxygenase	Homo sapiens	92-95
32042196-7	2020	The 6-month clinical response to ICB in patients with MM is associated with the large CD8+ T cell clone count 21 d after treatment and agnostic to clonal specificity, suggesting that post-ICB peripheral CD8+ clonality can provide information regarding long-term treatment response and, potentially, facilitate treatment stratification.	indole-2-carboxylic acid	33-36	CD8a molecule	Homo sapiens	86-89
32042196-7	2020	The 6-month clinical response to ICB in patients with MM is associated with the large CD8+ T cell clone count 21 d after treatment and agnostic to clonal specificity, suggesting that post-ICB peripheral CD8+ clonality can provide information regarding long-term treatment response and, potentially, facilitate treatment stratification.	indole-2-carboxylic acid	33-36	CD8a molecule	Homo sapiens	203-206
31101760-10	2019	Taken together, these results demonstrate that the efficacy of ICB in pancreatic cancer is enhanced by ATM inhibition and further potentiated by radiation as a function of increased tumoral immunogenicity, underscoring the potential of ATM inhibition in combination with ICB and radiation as an efficacious treatment strategy for pancreatic cancer.	indole-2-carboxylic acid	63-66	ATM serine/threonine kinase	Homo sapiens	236-239
30940655-9	2019	Moreover, RET and Src co-high expression was an independent unfavorable prognosis factor in melanoma patients with or without ICB through inhibiting the antitumor immune response.	indole-2-carboxylic acid	126-129	ret proto-oncogene	Homo sapiens	10-13
30940655-9	2019	Moreover, RET and Src co-high expression was an independent unfavorable prognosis factor in melanoma patients with or without ICB through inhibiting the antitumor immune response.	indole-2-carboxylic acid	126-129	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	18-21
30940655-10	2019	CONCLUSIONS: Our data unveiled a new mechanism of alleviating IFNgamma-induced PD-L1 and IDO1 expression and provided a rationale to explore a novel combination of ICB with regorafenib clinically, especially in melanoma with RET/Src axis activation.	indole-2-carboxylic acid	164-167	interferon gamma	Homo sapiens	62-70
30940655-10	2019	CONCLUSIONS: Our data unveiled a new mechanism of alleviating IFNgamma-induced PD-L1 and IDO1 expression and provided a rationale to explore a novel combination of ICB with regorafenib clinically, especially in melanoma with RET/Src axis activation.	indole-2-carboxylic acid	164-167	CD274 molecule	Homo sapiens	79-84
30940655-10	2019	CONCLUSIONS: Our data unveiled a new mechanism of alleviating IFNgamma-induced PD-L1 and IDO1 expression and provided a rationale to explore a novel combination of ICB with regorafenib clinically, especially in melanoma with RET/Src axis activation.	indole-2-carboxylic acid	164-167	indoleamine 2,3-dioxygenase 1	Homo sapiens	89-93
30940655-10	2019	CONCLUSIONS: Our data unveiled a new mechanism of alleviating IFNgamma-induced PD-L1 and IDO1 expression and provided a rationale to explore a novel combination of ICB with regorafenib clinically, especially in melanoma with RET/Src axis activation.	indole-2-carboxylic acid	164-167	ret proto-oncogene	Homo sapiens	225-228
30940655-10	2019	CONCLUSIONS: Our data unveiled a new mechanism of alleviating IFNgamma-induced PD-L1 and IDO1 expression and provided a rationale to explore a novel combination of ICB with regorafenib clinically, especially in melanoma with RET/Src axis activation.	indole-2-carboxylic acid	164-167	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	229-232
30497521-5	2018	We also discuss several mechanisms that have been observed to confer resistance to ICB, such as loss of phosphatase and tensin homolog (PTEN), loss of major histocompatibility complex (MHC) I/II expression, and activation of the indoleamine 2,3-dioxygenase 1 (IDO1) and transforming growth factor beta (TGFbeta) pathways.	indole-2-carboxylic acid	83-86	phosphatase and tensin homolog	Homo sapiens	136-140
31339548-16	2019	Conclusions and Relevance: In this study, baseline serum levels of monocyte chemoattractant protein 1, leukemia inhibitory factor, and cluster of differentiation 152 were associated with hyperprogressive metastatic gastrointestinal cancer among patients receiving ICB.	indole-2-carboxylic acid	264-267	C-C motif chemokine ligand 2	Homo sapiens	67-101
31339548-16	2019	Conclusions and Relevance: In this study, baseline serum levels of monocyte chemoattractant protein 1, leukemia inhibitory factor, and cluster of differentiation 152 were associated with hyperprogressive metastatic gastrointestinal cancer among patients receiving ICB.	indole-2-carboxylic acid	264-267	LIF interleukin 6 family cytokine	Homo sapiens	103-129
31339548-17	2019	An early decrease in serum interleukin 1 receptor antagonist levels in patients with metastatic ESCC or CRC and an early increase in serum brain-derived neurotrophic factor levels in patients with metastatic GC were better able to identify who would respond to ICB compared with microsatellite stability status or programmed cell death ligand 1 expression.	indole-2-carboxylic acid	261-264	brain derived neurotrophic factor	Homo sapiens	139-172
31309173-6	2019	Through several mouse models, we demonstrated that TNF neutralization ameliorated ICB-exacerbated colitis in addition to improving ICB-dependent anti-tumor efficacy.	indole-2-carboxylic acid	82-85	tumor necrosis factor	Mus musculus	51-54
31309173-6	2019	Through several mouse models, we demonstrated that TNF neutralization ameliorated ICB-exacerbated colitis in addition to improving ICB-dependent anti-tumor efficacy.	indole-2-carboxylic acid	131-134	tumor necrosis factor	Mus musculus	51-54
31069142-11	2019	WISP1 mRNA expression was associated with primary resistance to ICB in datasets showing EMT.	indole-2-carboxylic acid	64-67	cellular communication network factor 4	Homo sapiens	0-5
31112973-12	2019	The combination of EGFR inhibitors and ICB could help deepening the knowledge about the interrelations between the EGFR and PD-1/PD-L1 pathways.	indole-2-carboxylic acid	39-42	epidermal growth factor receptor	Homo sapiens	115-119
31112973-12	2019	The combination of EGFR inhibitors and ICB could help deepening the knowledge about the interrelations between the EGFR and PD-1/PD-L1 pathways.	indole-2-carboxylic acid	39-42	CD274 molecule	Homo sapiens	129-134
30518683-4	2018	We found that ICB can induce tumor rejection and protective immunity with these systems in a manner dependent on CD4+ T cells but not reliant on CD8+ T cells.	indole-2-carboxylic acid	14-17	CD4 molecule	Homo sapiens	113-116
30518683-5	2018	Evaluation of tumor infiltrates and draining lymph nodes after ICB revealed expansion of IFN-gamma-producing CD4+ T cells.	indole-2-carboxylic acid	63-66	interferon gamma	Homo sapiens	89-98
30518683-5	2018	Evaluation of tumor infiltrates and draining lymph nodes after ICB revealed expansion of IFN-gamma-producing CD4+ T cells.	indole-2-carboxylic acid	63-66	CD4 molecule	Homo sapiens	109-112
31246037-2	2019	In contrast, indole-2-carboxylic acids/amides form fused seven-membered lactones/lactams (oxepinoindolones/azepinoindolones) upon treatment with substituted propargyl alcohols using catalytic Cu(OTf)2.	indole-2-carboxylic acid	13-38	POU class 2 homeobox 2	Homo sapiens	195-200
31092729-4	2019	Here, we found that titin (TTN), which is frequently detected in solid tumors, is associated with increased TMB and correlated with objective response to ICB.	indole-2-carboxylic acid	154-157	titin	Homo sapiens	20-25
31092729-4	2019	Here, we found that titin (TTN), which is frequently detected in solid tumors, is associated with increased TMB and correlated with objective response to ICB.	indole-2-carboxylic acid	154-157	titin	Homo sapiens	27-30
31092729-7	2019	Identification of TTN mutation as a predictor of improved outcomes in response to ICBs provides a clinically feasible assessment for estimating TMB and ICB therapy outcomes.	indole-2-carboxylic acid	82-85	titin	Homo sapiens	18-21
30503610-1	2019	beta2-microglobulin (B2M), a component of major histocompatibility complex class I, plays an important role in host immune reaction to tumor, and inactivation of B2M is known to contribute to resistance to immune checkpoint blockade (ICB) treatment.	indole-2-carboxylic acid	234-237	beta-2-microglobulin	Homo sapiens	0-19
30503610-1	2019	beta2-microglobulin (B2M), a component of major histocompatibility complex class I, plays an important role in host immune reaction to tumor, and inactivation of B2M is known to contribute to resistance to immune checkpoint blockade (ICB) treatment.	indole-2-carboxylic acid	234-237	beta-2-microglobulin	Homo sapiens	21-24
30503610-1	2019	beta2-microglobulin (B2M), a component of major histocompatibility complex class I, plays an important role in host immune reaction to tumor, and inactivation of B2M is known to contribute to resistance to immune checkpoint blockade (ICB) treatment.	indole-2-carboxylic acid	234-237	beta-2-microglobulin	Homo sapiens	162-165
30503610-4	2019	Of note, bi-allelic B2M alterations, which had been known to be accumulated during ICB treatment, were frequently found (3/9) in ICB treatment-naive CRCs.	indole-2-carboxylic acid	83-86	beta-2-microglobulin	Homo sapiens	20-23
30503610-4	2019	Of note, bi-allelic B2M alterations, which had been known to be accumulated during ICB treatment, were frequently found (3/9) in ICB treatment-naive CRCs.	indole-2-carboxylic acid	129-132	beta-2-microglobulin	Homo sapiens	20-23
30503610-7	2019	Our results show that B2M mutation is common in MSU CRCs, which is one of the main targets for ICB treatment, suggesting that frequent B2M mutation status should be reminded for MSU CRCs in patient selection of ICB.	indole-2-carboxylic acid	95-98	beta-2-microglobulin	Homo sapiens	22-25
30503610-7	2019	Our results show that B2M mutation is common in MSU CRCs, which is one of the main targets for ICB treatment, suggesting that frequent B2M mutation status should be reminded for MSU CRCs in patient selection of ICB.	indole-2-carboxylic acid	211-214	beta-2-microglobulin	Homo sapiens	22-25
30497521-5	2018	We also discuss several mechanisms that have been observed to confer resistance to ICB, such as loss of phosphatase and tensin homolog (PTEN), loss of major histocompatibility complex (MHC) I/II expression, and activation of the indoleamine 2,3-dioxygenase 1 (IDO1) and transforming growth factor beta (TGFbeta) pathways.	indole-2-carboxylic acid	83-86	indoleamine 2,3-dioxygenase 1	Homo sapiens	229-258
30497521-5	2018	We also discuss several mechanisms that have been observed to confer resistance to ICB, such as loss of phosphatase and tensin homolog (PTEN), loss of major histocompatibility complex (MHC) I/II expression, and activation of the indoleamine 2,3-dioxygenase 1 (IDO1) and transforming growth factor beta (TGFbeta) pathways.	indole-2-carboxylic acid	83-86	indoleamine 2,3-dioxygenase 1	Homo sapiens	260-264
30497521-5	2018	We also discuss several mechanisms that have been observed to confer resistance to ICB, such as loss of phosphatase and tensin homolog (PTEN), loss of major histocompatibility complex (MHC) I/II expression, and activation of the indoleamine 2,3-dioxygenase 1 (IDO1) and transforming growth factor beta (TGFbeta) pathways.	indole-2-carboxylic acid	83-86	transforming growth factor beta 1	Homo sapiens	270-301
30497521-5	2018	We also discuss several mechanisms that have been observed to confer resistance to ICB, such as loss of phosphatase and tensin homolog (PTEN), loss of major histocompatibility complex (MHC) I/II expression, and activation of the indoleamine 2,3-dioxygenase 1 (IDO1) and transforming growth factor beta (TGFbeta) pathways.	indole-2-carboxylic acid	83-86	transforming growth factor beta 1	Homo sapiens	303-310
30006548-3	2018	Knockdown of KIF20A in NPCs causes dislocation of RGS3 from the intercellular bridge (ICB), impairs the function of Ephrin-B-RGS cell fate signaling complex, and leads to a transition from proliferative to differentiative divisions.	indole-2-carboxylic acid	86-89	kinesin family member 20A	Homo sapiens	13-19
30135306-9	2018	Thus, abnormal expression of piERVs is associated with ICA in several solid cancers, including ccRCC, and ERV3-2 expression is associated with response to ICB in ccRCC.	indole-2-carboxylic acid	155-158	endogenous retrovirus group 3 member 2	Homo sapiens	106-112
29898992-5	2018	Although radiotherapy technique (Tumor RT vs. ENI) affected initial tumor control and survival, the ability to reject tumor upon rechallenge was partially dependent upon the mechanism of action of ICB; as radiotherapy/anti-CTLA4 was superior to radiotherapy/anti-PD-1.Conclusions: Our results highlight that irradiation of the DLN restrains adaptive immune responses through altered chemokine expression and CD8+ T-cell trafficking.	indole-2-carboxylic acid	197-200	cytotoxic T-lymphocyte-associated protein 4	Mus musculus	223-228
30006548-3	2018	Knockdown of KIF20A in NPCs causes dislocation of RGS3 from the intercellular bridge (ICB), impairs the function of Ephrin-B-RGS cell fate signaling complex, and leads to a transition from proliferative to differentiative divisions.	indole-2-carboxylic acid	86-89	regulator of G protein signaling 3	Homo sapiens	50-54
29997292-4	2018	mCTLA4 levels were quantified using the Infinium HumanMethylation450 BeadChip (non-ICB cohort) and methylation-specific quantitative real-time PCR in DNA formalin-fixed and paraffin-embedded tissues (ICB cohort).	indole-2-carboxylic acid	83-86	cytotoxic T-lymphocyte-associated protein 4	Mus musculus	0-6
28912267-8	2017	Moreover, the ICB approach partially restored expression of several derepressed miR-155 targets in tumor-infiltrating, miR-155-deficient CD8+ T cells, suggesting that miR-155 and ICB regulate overlapping pathways to promote antitumor immunity.	indole-2-carboxylic acid	14-17	microRNA 155	Mus musculus	80-87
29997292-7	2018	In ICB-treated melanoma patients, low mCTLA4 was further strongly correlated with response to therapy (P = 0.009, ANOVA) and overall survival (hazard ratio = 2.06 [95% CI: 1.29-3.29], P = 0.003).	indole-2-carboxylic acid	3-6	cytotoxic T-lymphocyte-associated protein 4	Mus musculus	38-44
29997292-8	2018	Our data strongly support the assumption that mCTLA4 predicts response to both anti-PD-1 and anti-CTLA-4 targeted ICB in melanoma and provides paramount information for the selection of patients likely to respond to ICB.	indole-2-carboxylic acid	114-117	cytotoxic T-lymphocyte-associated protein 4	Mus musculus	46-52
29997292-8	2018	Our data strongly support the assumption that mCTLA4 predicts response to both anti-PD-1 and anti-CTLA-4 targeted ICB in melanoma and provides paramount information for the selection of patients likely to respond to ICB.	indole-2-carboxylic acid	114-117	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	98-104
29664018-6	2018	Mechanistically, CD8+ T cell depletion, IFN-gamma neutralization, or implantation of tumors in IFN-gamma receptor knockout mice abrogated the vessel perfusion enhancement and antitumor effects of ICB.	indole-2-carboxylic acid	196-199	interferon gamma	Mus musculus	40-49
29664018-6	2018	Mechanistically, CD8+ T cell depletion, IFN-gamma neutralization, or implantation of tumors in IFN-gamma receptor knockout mice abrogated the vessel perfusion enhancement and antitumor effects of ICB.	indole-2-carboxylic acid	196-199	interferon gamma	Mus musculus	95-104
29664018-7	2018	These results demonstrated that ICB increased vessel perfusion by promoting CD8+ T cell accumulation and IFN-gamma production, indicating that increased vessel perfusion reflects the successful activation of antitumor T cell immunity by ICB.	indole-2-carboxylic acid	32-35	interferon gamma	Homo sapiens	105-114
29642147-1	2018	PURPOSE: Using bibliometrics, we analyzed the research status of immune checkpoint blockade (ICB, a popular tumor immunotherapy method represented by antibodies targeted CTLA-4 and PD-1/PD-L1) in tumor immunotherapy in China during the past 2 decades.	indole-2-carboxylic acid	93-96	cytotoxic T-lymphocyte associated protein 4	Homo sapiens	170-176
29642147-1	2018	PURPOSE: Using bibliometrics, we analyzed the research status of immune checkpoint blockade (ICB, a popular tumor immunotherapy method represented by antibodies targeted CTLA-4 and PD-1/PD-L1) in tumor immunotherapy in China during the past 2 decades.	indole-2-carboxylic acid	93-96	programmed cell death 1	Homo sapiens	181-185
29642147-1	2018	PURPOSE: Using bibliometrics, we analyzed the research status of immune checkpoint blockade (ICB, a popular tumor immunotherapy method represented by antibodies targeted CTLA-4 and PD-1/PD-L1) in tumor immunotherapy in China during the past 2 decades.	indole-2-carboxylic acid	93-96	CD274 molecule	Homo sapiens	186-191
29029813-5	2017	Several basic and translational mechanisms of resistance to immune checkpoint blockers (ICBs) were discussed during the meeting: 1. the impact of tumor microenvironment on the activity of immune system; 2. strategies to inhibit the cross-talk between extracellular matrix and myeloid-derived suppressor cells (MDSC) in the preclinical setting; 3. microRNA expression as a biomarker and as a target of therapy in non-small cell lung cancer (NSCLC); 4. the significance of complement activation pathways in response to immune checkpoint inhibitors; 5. the immunosuppressive activity of the microbiota by inducing IL-17 producing cells; and 6. modulation of HLA antigens as possible markers of response to ICB therapy.	indole-2-carboxylic acid	88-91	interleukin 17A	Homo sapiens	611-616
28912267-8	2017	Moreover, the ICB approach partially restored expression of several derepressed miR-155 targets in tumor-infiltrating, miR-155-deficient CD8+ T cells, suggesting that miR-155 and ICB regulate overlapping pathways to promote antitumor immunity.	indole-2-carboxylic acid	14-17	microRNA 155	Mus musculus	119-126
28912267-8	2017	Moreover, the ICB approach partially restored expression of several derepressed miR-155 targets in tumor-infiltrating, miR-155-deficient CD8+ T cells, suggesting that miR-155 and ICB regulate overlapping pathways to promote antitumor immunity.	indole-2-carboxylic acid	14-17	microRNA 155	Mus musculus	119-126
27939310-7	2017	MKlp2 recruits Aurora B to the ICB [11-15].	indole-2-carboxylic acid	31-34	aurora kinase B	Homo sapiens	15-23
29163786-6	2017	Thus, Axl-directed therapy in Axl expressing tumors could hold a great potential to subvert the innate and/or adaptive resistance to and broaden the coverage of population benefited from ICB-based immunotherapy.	indole-2-carboxylic acid	187-190	AXL receptor tyrosine kinase	Mus musculus	6-9
29163786-6	2017	Thus, Axl-directed therapy in Axl expressing tumors could hold a great potential to subvert the innate and/or adaptive resistance to and broaden the coverage of population benefited from ICB-based immunotherapy.	indole-2-carboxylic acid	187-190	AXL receptor tyrosine kinase	Mus musculus	30-33
27939310-6	2017	We identify MKlp2 as an essential protein for promoting abscission, which may regulate tethering and stabilizing of the PM to the microtubule cytoskeleton at the ICB through its previously uncharacterized lipid association motif (LAM).	indole-2-carboxylic acid	162-165	kinesin family member 20A	Homo sapiens	12-17
27828943-8	2016	Furthermore, selective pharmacologic targeting of the gamma isoform of phosphoinositide 3-kinase (PI3Kgamma), highly expressed in myeloid cells, restores sensitivity to ICB.	indole-2-carboxylic acid	169-172	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma	Homo sapiens	98-107
27939310-7	2017	MKlp2 recruits Aurora B to the ICB [11-15].	indole-2-carboxylic acid	31-34	kinesin family member 20A	Homo sapiens	0-5
28002724-4	2016	(2016) demonstrate that sustained interferon signaling is central to the development of PD-L1-dependent and -independent resistance to ICB.	indole-2-carboxylic acid	135-138	CD274 molecule	Homo sapiens	88-93
27828943-10	2016	Our results introduce opportunities for new combination strategies using a selective small molecule PI3Kgamma inhibitor, such as IPI-549, to overcome resistance to ICB in patients with high levels of suppressive myeloid cell infiltration in tumours.	indole-2-carboxylic acid	164-167	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma	Homo sapiens	100-109
23000966-4	2012	We characterize the role of FIP3 endosomes during cytokinesis to demonstrate that FIP3 endosomes deliver SCAMP2/3 and p50RhoGAP to the ICB during late telophase, proteins required for the formation of the secondary ingression.	indole-2-carboxylic acid	135-138	inhibitor of nuclear factor kappa B kinase regulatory subunit gamma	Homo sapiens	28-32
25590800-3	2015	Here, we describe a series of indole-2-carboxylic acids, exemplified by the compound A-1210477, that bind to MCL-1 selectively and with sufficient affinity to disrupt MCL-1-BIM complexes in living cells.	indole-2-carboxylic acid	30-55	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	109-114
25590800-3	2015	Here, we describe a series of indole-2-carboxylic acids, exemplified by the compound A-1210477, that bind to MCL-1 selectively and with sufficient affinity to disrupt MCL-1-BIM complexes in living cells.	indole-2-carboxylic acid	30-55	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	167-172
25844895-4	2015	Here, we describe the discovery of potent tricyclic 2-indole carboxylic acid inhibitors that exhibit single digit nanomolar binding affinity to Mcl-1 and greater than 1700-fold selectivity over Bcl-xL and greater than 100-fold selectivity over Bcl-2.	indole-2-carboxylic acid	52-76	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	144-149
25844895-4	2015	Here, we describe the discovery of potent tricyclic 2-indole carboxylic acid inhibitors that exhibit single digit nanomolar binding affinity to Mcl-1 and greater than 1700-fold selectivity over Bcl-xL and greater than 100-fold selectivity over Bcl-2.	indole-2-carboxylic acid	52-76	BCL2 like 1	Homo sapiens	194-200
25844895-4	2015	Here, we describe the discovery of potent tricyclic 2-indole carboxylic acid inhibitors that exhibit single digit nanomolar binding affinity to Mcl-1 and greater than 1700-fold selectivity over Bcl-xL and greater than 100-fold selectivity over Bcl-2.	indole-2-carboxylic acid	52-76	BCL2 apoptosis regulator	Homo sapiens	244-249
23000966-4	2012	We characterize the role of FIP3 endosomes during cytokinesis to demonstrate that FIP3 endosomes deliver SCAMP2/3 and p50RhoGAP to the ICB during late telophase, proteins required for the formation of the secondary ingression.	indole-2-carboxylic acid	135-138	inhibitor of nuclear factor kappa B kinase regulatory subunit gamma	Homo sapiens	82-86
23000966-4	2012	We characterize the role of FIP3 endosomes during cytokinesis to demonstrate that FIP3 endosomes deliver SCAMP2/3 and p50RhoGAP to the ICB during late telophase, proteins required for the formation of the secondary ingression.	indole-2-carboxylic acid	135-138	secretory carrier membrane protein 2	Homo sapiens	105-113
23000966-4	2012	We characterize the role of FIP3 endosomes during cytokinesis to demonstrate that FIP3 endosomes deliver SCAMP2/3 and p50RhoGAP to the ICB during late telophase, proteins required for the formation of the secondary ingression.	indole-2-carboxylic acid	135-138	Rho GTPase activating protein 1	Homo sapiens	118-127